ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1006

Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort

Carine Salliot1, Yann Nguyen2, Amandine Gelot3, Xavier Mariette4, Marie-Christine Boutron-Ruault3 and Raphaèle Seror5, 1CHR orleans, Orleans, France, 21Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, 3Institut Gustave Roussy, Villejuif, France, 4Paris-Sud University, Rueil-Malmaison, France, 5Rheumatology Department, Bicetre Hospital, APHP, France, Paris, France

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Hormone Replacement Therapy, rheumatoid arthritis, risk assessment, Women's health

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The involvement of female hormones in the pathogenesis of Rheumatoid Arthritis (RA) is supported by numerous observations: a female predominance, an increased incidence in the post-partum, and around the age of menopause. In the literature, findings on the association between reproductive and hormonal factors, taken individually, and RA are conflicting. Our objectives were to assess the relationships between lifetime durations/level of female hormonal exposures and the risk of RA.

Methods: E3N is an ongoing French prospective cohort of 98,995 women since 1990 aged 40-65 years at enrolment. Validation of RA cases among the cohort has been previously published [Nguyen et al. BMJ Open 2019]. Lifetime female hormonal exposures were defined as follows:

–  Reproductive span (in years) = duration from menarche to menopause

– Total ovulatory years (in years, time-dependent) = Reproductive span – (number of full-term pregnancies x 0.75 + number of miscarriages x 0.25 + total duration of breast feeding + total duration of oral contraception)

– Lifetime hormonal exposure (in years, time-dependent) = Reproductive span + total duration of menopausal hormonal therapy

– Composite Estrogen Score (CES, range = 0–5, time-dependent), calculated by point assignment for early menarche (≤10 years), high parity ( >3 pregnancies), history of hysterectomy, use of hormone therapy (oral contraception and/or menopausal hormonal therapy, ever) and late menopause (≥53 years).

Hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of incident RA were estimated using Cox proportional hazards regression models with age as the time scale.

Models were adjusted for age (age-adjusted model) and additionally for smoking, passive smoking during childhood, educational level, body mass index , duration of premenopausal progestogen, age at the first pregnancy  and type of menopause (multi-adjusted model).

Results: A total of 637 incident RA cases occurred among 78,391 post-menopausal women with a total of 1,864,915 women-years from baseline.

Reproductive span, total ovulatory years and lifetime hormonal exposure were not significantly associated with incident RA in postmenopausal women in age adjusted models (p for trend=0.2479, p for trend=0.4343, p for trend=0.9216 , respectively).

In multivariable-adjusted Cox regression models, high level of estrogen exposure (CES=3-5) was inversely associated with the risk of RA in post-menopausal women: HR=0.65 (95%CI 0.4–0.9), p=0.04, taking low level (CES=0-1) as reference (Table).

Interestingly, in a recent publication, high level of CES was associated with a reduced risk of primary Sjögren, but not cumulative menstrual cycling (reproductive span minus time to pregnant) [McCoy et al. Arthritis Care Res 2019]. RA and primary Sjögren share a marked female predominance with a peak onset around menopause and the participation of B lymphocytes in this physiopathology.

Conclusion: In E3N cohort, a high CES which reflects lifetime exposure to estrogen was associated with a decreased risk of RA in postmenopausal women.


Disclosure: C. Salliot, None; Y. Nguyen, None; A. Gelot, None; X. Mariette, None; M. Boutron-Ruault, None; R. Seror, None.

To cite this abstract in AMA style:

Salliot C, Nguyen Y, Gelot A, Mariette X, Boutron-Ruault M, Seror R. Post-menopausal Rheumatoid Arthritis Is Inversely Associated with Lifetime High Level of Estrogen Exposure in the French E3N Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/post-menopausal-rheumatoid-arthritis-is-inversely-associated-with-lifetime-high-level-of-estrogen-exposure-in-the-french-e3n-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-menopausal-rheumatoid-arthritis-is-inversely-associated-with-lifetime-high-level-of-estrogen-exposure-in-the-french-e3n-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology